Immunotherapy and vaccination after transplant: The present, the future

Infectious Disease Clinics of North America

Volumn 24, Issue 2, 2010, Pages 515-529

  Emery, Vincent C ^a   Einsele, Hermann ^b   Atabani, Sowsan ^a,c   Haque, Tanzina ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cytomegalovirus; Epstein Barr virus; Papillomavirus; Varicella zoster virus

Indexed keywords

ADENOVIRUS VECTOR; ALPHAVAX; ANTILEUKEMIC AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CANARYPOX PP 65; CD4 ANTIGEN; CD8 ANTIGEN; CELL CYCLE PROTEIN; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; DNA VACCINE; GAMMA INTERFERON; GB; GLYCOPROTEIN B; HEPATITIS B VACCINE; HLA ANTIGEN; IMMUNOGLOBULIN; LIVE VACCINE; PLACEBO; PREDNISOLONE; RECOMBINANT VACCINE; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TACROLIMUS; TOWNE; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS DNA; WART VIRUS VACCINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOVIRUS INFECTION; ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; BONE MARROW TOXICITY; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEPATITIS B; HERPES SIMPLEX; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION CONTROL; INFECTION RISK; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; NEPHROTOXICITY; NONHUMAN; REVIEW; SEROCONVERSION; T LYMPHOCYTE; VACCINATION; VIRUS LOAD; VIRUS REPLICATION;

COMMUNICABLE DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; TRANSPLANTATION; VACCINATION;

EID: 77952714684     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.01.004     Document Type: Review

References (90)

1. Fischer S.A. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation 2008, 86(10):1327-1339.
2. Saral R., Burns W.H., Laskin O.L., et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981, 305(2):63-67.
3. Sempere A., Sanz G.F., Senent L., et al. Long-term acyclovir prophylaxis for prevention of varicella zoster virus infection after autologous blood stem cell transplantation in patients with acute leukemia. Bone Marrow Transplant 1992, 10(6):495-498.
4. Khoury J.A., Storch G.A., Bohl D.L., et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006, 6(9):2134-2143.
5. Paya C., Humar A., Dominguez E., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4(4):611-620.
6. Boivin G., Goyette N., Rollag H., et al. Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir. Antivir Ther 2009, 14(5):697-704.
7. Plotkin S.A., Huygelen C. Cytomegalovirus vaccine prepared in WI-38. Dev Biol Stand 1976, 37:301-305.
8. Glazer J.P., Friedman H.M., Grossman R.A., et al. Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial. Ann Intern Med 1979, 91(5):676-683.
9. Plotkin S.A., Smiley M.L., Friedman H.M., et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1984, 1(8376):528-530.
10. Pass R.F., Duliege A.M., Boppana S., et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999, 180(4):970-975.
11. Adler S.P., Plotkin S.A., Gonczol E., et al. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 1999, 180(3):843-846.
12. Reap E.A., Dryga S.A., Morris J., et al. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins. Clin Vaccine Immunol 2007, 14(6):748-755.
13. Temperton N.J. DNA vaccines against cytomegalovirus: current progress. Int J Antimicrob Agents 2002, 19(3):169-172.
14. Griffiths P.D., McLean A., Emery V.C. Encouraging prospects for immunisation against primary cytomegalovirus infection. Vaccine 2001, 19(11-12):1356-1362.
15. Emery V.C., Hassan-Walker A.F., Burroughs A.K., et al. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts. J Infect Dis 2002, 185(12):1723-1728.
16. Emery V.C. Viral dynamics during active cytomegalovirus infection and pathology. Intervirology 1999, 42(5-6):405-411.
17. Wagner B., Kropff B., Kalbacher H., et al. A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. J Virol 1992, 66(9):5290-5297.
18. Marshall G.S., Li M., Stout G.G., et al. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients. Viral Immunol 2000, 13(3):329-341.
19. Schleiss M.R., Bourne N., Stroup G., et al. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis 2004, 189(8):1374-1381.
20. Pass R.F., Burke R.L. Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection. Semin Pediatr Infect Dis 2002, 13(3):196-204.
21. Mitchell D.K., Holmes S.J., Burke R.L., et al. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002, 21(2):133-138.
22. Pass R.F. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J Clin Virol 2009, 46:S73-6.
23. Pass R.F., Zhang C., Evans A., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360(12):1191-1199.
24. Tan H.H., Goh C.L. Viral infections affecting the skin in organ transplant recipients: epidemiology and current management strategies. Am J Clin Dermatol 2006, 7(1):13-29.
25. Albright J.B., Bonatti H., Stauffer J., et al. Colorectal and anal neoplasms following liver transplantation. Colorectal Dis 2009, [Epub ahead of print].
26. Roka S., Rasoul-Rockenschaub S., Roka J., et al. Prevalence of anal HPV infection in solid-organ transplant patients prior to immunosuppression. Transpl Int 2004, 17:366-369.
27. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006, 367(9518):1247-1255.
28. FUTURE II Study Group Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007, 356(19):1915-1927.
29. Wong G., Howard K., Webster A., et al. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation 2009, 87(7):1078-1091.
30. Safety and immunogenicity of human papillomavirus (HPV) vaccine in solid organ transplant recipients; 2009. Available at: Accessed January 26, 2010. http://www.clinicaltrials.gov/ct2/show/NCT00677677.
31. Gershon A.A., Katz S.L. Perspective on live varicella vaccine. J Infect Dis 2008, 197(Suppl 2):242-245.
32. Milone G., Di Raimondo F., Russo M., et al. Unusual onset of severe varicella in adult immunocompromised patients. Ann Hematol 1992, 64:155-156.
33. Yagi T., Karasumo T., Hasegawa T., et al. Acute abdomen without cutaneous signs of varicella zoster virus infection as a late complication of allogeneic bone marrow transplantation: importance of empiric therapy with aciclovir. Bone Marrow Transplant 2000, 25:1003-1005.
34. Hovens M.M.C., Vaessen N., Sijpkens Y.W.J., et al. Unusual presentation of central nervous system manifestations of varicella zoster virus vasculopathy in renal transplant recipients. Transpl Infect Dis 2007, 9:237-240.
35. Varicella. In: The green book: immunization against infectious disease. London (UK): Department of Health 2006, chapter 34.
36. Sartori A.M.C. A review of the varicella vaccine in immunocompromised individuals. Int J Infect Dis 2004, 8:259-270.
37. Gershon A.A., Steinbert S.P., Gelb L., et al. Live attenuated varicella vaccine, efficacy for children with leukemia in remission. JAMA 1984, 252:355-362. The national institute of allergy and infectious diseases varicella vaccine collaborative study group.
38. Hardy I.B., Gershon A., Steinberg S., et al. The incidence of zoster after immunization with live attenuated varicella vaccine: a study in children with leukemia. N Engl J Med 1991, 325:1545-1550.
39. Levin M.J., Gershon A.A., Weingberg A., et al. Immunization of HIV-infected children with varicella vaccine. J Pediatr 2001, 139:305-310.
40. Gershon A.A., Levin M.J., Weinberg A., et al. A phase II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus infected children with previous varicella. Pediatr Infect Dis J 2009, 28:653-655.
41. Geretti A.M., BHIVA Immunization Writing Committee British HIV Association guidelines for immunization of HIV-infected adults in 2008. HIV Med 2008, 9:795-848.
42. Weinberg A., Horslen S.P., Kaufmann S.S., et al. Safety and immunogenicity of varicella-zoster virus vaccine in pediatric liver and intestine transplant recipients. Am J Transplant 2006, 6:565-568.
43. Gershon A.A. Varicella vaccine: rare serious problems: but the benefits still outweigh the risks. J Infect Dis 2003, 188:945-947.
44. Barraclough K.A., Wiggins K.J., Hawley C.M., et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in nonresponders to primary vaccination. Am J Kidney Dis 2009, 54(1):95-103.
45. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin Biol Ther 2008, 8(2):235-247.
46. Gandhi M.K., Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004, 4(12):725-738.
47. Lilley B.N., Ploegh H.L. Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol Rev 2005, 207:126-144.
48. Peggs K.S. Adoptive T cell immunotherapy for cytomegalovirus. Expert Opin Biol Ther 2009, 9(6):725-736.
49. Einsele H., Rauser G., Grigoleit U., et al. Induction of CMV-specific T-cell lines using Ag-presenting cells pulsed with CMV protein or peptide. Cytotherapy 2002, 4(1):49-54.
50. Peggs K., Verfuerth S., Mackinnon S. Induction of cytomegalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood 2001, 97(4):994-1000.
51. Koehne G., Gallardo H.F., Sadelain M., et al. Rapid selection of antigen-specific T lymphocytes by retroviral transduction. Blood 2000, 96(1):109-117.
52. Riddell S.R., Watanabe K.S., Goodrich J.M., et al. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992, 257(5067):238-241.
53. Walter E.A., Greenberg P.D., Gilbert M.J., et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995, 333(16):1038-1044.
54. Einsele H., Roosnek E., Rufer N., et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002, 99(11):3916-3922.
55. Cobbold M., Khan N., Pourgheysari B., et al. Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med 2005, 202(3):379-386.
56. Fujita Y., Leen A.M., Sun J., et al. Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother 2008, 31(7):665-674.
57. Nebbia G., Mattes F.M., Smith C., et al. Polyfunctional cytomegalovirus-specific CD4+ and pp65 CD8+ T cells protect against high-level replication after liver transplantation. Am J Transplant 2008, 8:2590-2599.
58. La R.C., Krishnan A., Longmate J., et al. Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis 2008, 197(1):25-33.
59. Egli A., Binet I., Binggeli S., et al. Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med 2008, 6:29.
60. Szmania S., Galloway A., Bruorton M., et al. Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood 2001, 98(3):505-512.
61. Tan R., Xu X., Ogg G.S., et al. Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome. Blood 1999, 93(5):1506-1510.
62. Fletcher J.M., Vukmanovic-Stejic M., Dunne P.J., et al. Cytomegalovirus-specific CD4+ T cells in healthy carriers are continuously driven to replicative exhaustion. J Immunol 2005, 175(12):8218-8225.
63. Sylwester A.W., Mitchell B.L., Edgar J.B., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202(5):673-685.
64. Burns D.M., Crawford D.H. Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev 2004, 18(3):193-209.
65. Starzl T.E., Nalesnik M.A., Porter K.A., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984, 1(8377):583-587.
66. Swinnen L.J., Mullen G.M., Carr T.J., et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995, 86(9):3333-3340.
67. Choquet S., Leblond V., Herbrecht R., et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006, 107(8):3053-3057.
68. Opelz G., Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4(2):222-230.
69. Timms J.M., Bell A., Flavell J.R., et al. Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet 2003, 361(9353):217-223.
70. Khanna R., Burrows S.R. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol 2000, 54:19-48.
71. Rooney C.M., Smith C.A., Ng C.Y., et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345(8941):9-13.
72. Rooney C.M., Smith C.A., Ng C.Y., et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998, 92(5):1549-1555.
73. Haque T., Amlot P.L., Helling N., et al. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients. J Immunol 1998, 160(12):6204-6209.
74. Khanna R., Bell S., Sherritt M., et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A 1999, 96(18):10391-10396.
75. Savoldo B., Huls M.H., Liu Z., et al. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002, 100(12):4059-4066.
76. Haque T., Taylor C., Wilkie G.M., et al. Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation 2001, 72(8):1399-1402.
77. Wilkie G.M., Taylor C., Jones M.M., et al. Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of Epstein-Barr virus-associated diseases. J Immunother 1997, 27(4):309-316.
78. Haque T., Wilkie G.M., Taylor C., et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002, 360(9331):436-442.
79. Haque T., Wilkie G.M., Jones M.M., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110(4):1123-1131.
80. Khanna R., Burrows S.R., Nicholls J., et al. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998, 28(2):451-458.
81. Gottschalk S., Edwards O.L., Sili U., et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003, 101(5):1905-1912.
82. Sing A.P., Ambinder R.F., Hong D.J., et al. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997, 89(6):1978-1986.
83. Eshhar Z., Waks T., Gross G., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993, 90(2):720-724.
84. Sadelain M., Brentjens R., Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 2009, 21(2):215-223.
85. Chakrabarti S., Mautner V., Osman H., et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002, 100(5):1619-1627.
86. Bordigoni P., Carret A.S., Venard V., et al. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001, 32(9):1290-1297.
87. Feuchtinger T., Matthes-Martin S., Richard C., et al. Safe adoptive transfer of virus-specific T-cell immunity for the treatment of systemic adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2006, 134(1):64-76.
88. Feuchtinger T., Richard C., Joachim S., et al. Clinical grade generation of hexon-specific T cells for adoptive T-cell transfer as a treatment of adenovirus infection after allogeneic stem cell transplantation. J Immunother 2008, 31(2):199-206.
89. Karlsson H., Brewin J., Kinnon C., et al. Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus, and Epstein-Barr virus: an approach for adoptive immunotherapy of multiple pathogens. J Immunother 2007, 30(5):544-556.
90. Hanley P.J., Cruz C.R., Savoldo B., et al. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood 2009, 114(9):1958-1967.